Contact
searchSearch
HMP Global

News

News
Epcoritamab Shows Superior Responses vs Chemoimmunotherapy in Relapsed Follicular Lymphoma
03/11/2026
Hannah Musick
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of...
03/11/2026
First Report Managed Care
News
Aetna Reaches $117.7M Settlement in False Claims Act Violation
03/11/2026
Danielle Sposato
Aetna Inc. has agreed to pay $117.7 million to resolve allegations that it violated the False Claims Act by submitting or failing to withdraw inaccurate diagnosis codes for Medicare Advantage (MA) enrollees, resulting in inflated payments...
Aetna Inc. has agreed to pay $117.7 million to resolve allegations that it violated the False Claims Act by submitting or failing to withdraw inaccurate diagnosis codes for Medicare Advantage (MA) enrollees, resulting in inflated payments...
Aetna Inc. has agreed to pay...
03/11/2026
First Report Managed Care
News
Geographic Gaps Delay CAR T Therapy in Patients With DLBCL
03/10/2026
Grace Taylor, MS, MA
Geographic barriers to CAR T-cell therapy may be adding weeks of delay for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), raising concerns about timely access to potentially life-saving treatment.
Geographic barriers to CAR T-cell therapy may be adding weeks of delay for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), raising concerns about timely access to potentially life-saving treatment.
Geographic barriers to CAR...
03/10/2026
First Report Managed Care
News
CNS-Active Polypharmacy Affects 10 Percent of Medicare MTM Enrollees in the US
03/06/2026
Hannah Musick
In a nationally representative Medicare Medication Therapy Management (MTM) cohort, 10.7% of enrollees experienced central nervous system (CNS)-active polypharmacy, yet only about one-third completed a comprehensive medication review,...
In a nationally representative Medicare Medication Therapy Management (MTM) cohort, 10.7% of enrollees experienced central nervous system (CNS)-active polypharmacy, yet only about one-third completed a comprehensive medication review,...
In a nationally representative...
03/06/2026
First Report Managed Care
News
GLOBIN Study Reports Promising First-Line Outcomes in Follicular Lymphoma
03/06/2026
Grace Taylor, MS, MA
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus...
03/06/2026
First Report Managed Care
News
Arthritis Activity Limitations Affect Nearly Half of US Adults
03/06/2026
Grace Taylor, MS, MA
Nearly half of US adults with arthritis reported activity limitations in 2023, underscoring persistent functional burden and missed national targets to reduce disability.
Nearly half of US adults with arthritis reported activity limitations in 2023, underscoring persistent functional burden and missed national targets to reduce disability.
Nearly half of US adults with...
03/06/2026
First Report Managed Care
News
Outpatient Management of Grade 1 CRS Safe in R/R Follicular Lymphoma
03/05/2026
Hannah Musick
In a multicenter US cohort of patients with relapsed or refractory (R/R) follicular lymphoma, grade 1 cytokine release syndrome (CRS) following bispecific antibody therapy was safely managed in the outpatient setting without compromising...
In a multicenter US cohort of patients with relapsed or refractory (R/R) follicular lymphoma, grade 1 cytokine release syndrome (CRS) following bispecific antibody therapy was safely managed in the outpatient setting without compromising...
In a multicenter US cohort of...
03/05/2026
First Report Managed Care
News
Enhancing Prediction of Long-Term Survival After CAR T in DLBCL
03/05/2026
Hannah Musick
In a single-center US cohort of patients with diffuse large B-cell lymphoma (DLBCL), achieving event-free survival at 12 months after CAR T therapy was associated with durable remission and a 68% 5-year progression-free survival rate.
In a single-center US cohort of patients with diffuse large B-cell lymphoma (DLBCL), achieving event-free survival at 12 months after CAR T therapy was associated with durable remission and a 68% 5-year progression-free survival rate.
In a single-center US cohort of...
03/05/2026
First Report Managed Care
News
NHANES Data Highlight Growing Severe Obesity Burden in US Adults
03/05/2026
Grace Taylor, MS, MA
New National Health and Nutrition Examination Survey (NHANES) data show that more than 40% of U.S. adults have obesity, with severe obesity continuing to rise and persistent disparities across age, sex, and racial groups.
New National Health and Nutrition Examination Survey (NHANES) data show that more than 40% of U.S. adults have obesity, with severe obesity continuing to rise and persistent disparities across age, sex, and racial groups.
New National Health and...
03/05/2026
First Report Managed Care
News
AI Roadmap Aims to Accelerate Nephrology Clinical Integration in US Care
03/04/2026
Hannah Musick
A state-of-the-art review outlines how artificial intelligence (AI) could enhance prediction, personalization, and workflow efficiency across acute kidney injury, chronic kidney disease, dialysis, and transplantation, while emphasizing the...
A state-of-the-art review outlines how artificial intelligence (AI) could enhance prediction, personalization, and workflow efficiency across acute kidney injury, chronic kidney disease, dialysis, and transplantation, while emphasizing the...
A state-of-the-art review...
03/04/2026
First Report Managed Care

Pipeline Projections

Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care
Pipeline Projections
Examining Newly FDA-Approved Anticoagulants and Upcoming Drugs in the Approval Pipeline
02/12/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline...
02/12/2025
First Report Managed Care

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use